Related Experiment Video
Updated: Oct 23, 2025
08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
9.3K
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple
Heinz Wiendl1, Ralf Gold2, Thomas Berger3
1Klinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149 Münster.
Therapeutic Advances in Neurological Disorders
|August 23, 2021
Summary
This 2021 update provides key recommendations for disease-modifying therapies for multiple sclerosis (MS), an autoimmune central nervous system disease. Evidence-based guidance aids treatment decisions for MS patients in German-speaking regions.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a complex autoimmune disorder affecting the central nervous system.
- It involves inflammatory demyelination and axonal/neuronal damage.
- Recent advancements have improved understanding and altered MS prognosis.
Purpose of the Study:
- To update treatment recommendations for disease-modifying therapies (DMTs) in multiple sclerosis for 2021.
- To focus on the most crucial recommendations for MS management.
- To provide evidence-based guidance for clinicians.
Main Methods:
- Review of current scientific evidence on DMTs for MS.
- Focus on medications approved in Europe, specifically German-speaking countries.
- Consensus-based recommendations from the Multiple Sclerosis Therapy Consensus Group.
Main Results:
- The update emphasizes key recommendations for DMTs in multiple sclerosis.
- It incorporates recent understanding of MS disease mechanisms and evolution.
- Recommendations are based on scientific evidence for approved medications.
Conclusions:
- Updated 2021 recommendations guide the use of DMTs for multiple sclerosis.
- These guidelines reflect advancements in MS treatment and understanding.
- The recommendations are applicable to German-speaking regions (Germany, Austria, Switzerland).
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
01:28Drug Therapy
121
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
121
01:22Alzheimer's Disease: Treatment
412
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
412
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
262
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
262
01:15Parkinson's Disease: Overview
981
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
981
01:24Parkinson's Disease: Treatment
562
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
562